10-(3-氯丙基)吩噻嗪 | 5909-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 10-(3-氯丙基)吩噻嗪
• 英文名称: 10-(3-chloropropyl)-10H-phenothiazine
• 英文别名: 10-(3-chloropropyl)phenothiazine
• CAS: 5909-59-1
• 化学式: C₁₅H₁₄ClNS
• mdl: MFCD11521646
• 分子量: 275.802
• InChiKey: DLCIJMPSJTVVHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934300000

反应信息

• 作为反应物：
  描述：

  10-(3-氯丙基)吩噻嗪 在 lithium aluminium tetrahydride 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 4-[4-(3-phenothiazin-10-ylpropyl)piperazin-1-yl]butylamine
  参考文献：
  名称：

  A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives:  Design, Synthesis, and Biological Investigations

  摘要：

  Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC50 value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.

  DOI：

  10.1021/jm060773j
• 作为产物：
  描述：

  β-(10-Phenothiazyl)propionic acid ethyl ester 在 吡啶 、 lithium aluminium tetrahydride 、 水 、 三氯氧磷 作用下， 以 乙醚 、 氯仿 为溶剂， 反应 15.5h， 生成 10-(3-氯丙基)吩噻嗪
  参考文献：
  名称：

  Ultrafast Electrochromic Windows Based on Redox-Chromophore Modified Nanostructured Semiconducting and Conducting Films

  摘要：

  Described is the construction of an ultrafast electrochromic window. One electrode of this window is based on a transparent nanostructured TiO2 (anatase) film (4.0 mum. thick) supported on conducting glass (F-doped tin oxide, 10 Ohm cm(-2), 0.5 mum thick) and modified by chemisorption of a monolayer of the redox chromophore bis(2-phosphonoethyl)-4,4'-bipyridinium dichloride. The other electrode is based on a transparent nanostructured SnO2 film (3.0 mum thick) supported on conducting glass (F-doped tin oxide, 10 Ohm cm-2, 0.5 mum thick) and modified by chemisorption of a monolayer of the redox chromophore [beta-(10-phenothiazyl)propoxy]phosphonic acid. The electrolyte used is LiClO4 (0.2 mol dm(-3)) in gamma -butyrolactone. The excellent performance of a 2.5 cm x 2.5 cm window over 10 000 electrochromic test cycles-switching times (coloring and bleaching) of less than 250 ms, coloration efficiency of 270 cm(2) C-1, steady-state currents (colored and bleached) of less than 6 muA cm(-2), and memory of greater than 600 s (time required for low end transmittance to increase by 5%)-suggest a practical technology.

  DOI：

  10.1021/jp001763b

文献信息

• 吩噻嗪类化合物及其应用
  申请人：天津国际生物医药联合研究院

  公开号：CN109761932A

  公开（公告）日：2019-05-17

  本发明提供了吩噻嗪类化合物及其在制备乳腺癌和黑色素瘤的药物中的应用。吩噻嗪类化合物对乳腺癌细胞MDA‑MB‑231、SUM159、MCF‑7、SKBR‑3和黑色素瘤细胞A375、B16BL6的抑制活性高于三氟拉嗪和硫利达嗪，可以应用于治疗乳腺癌和黑色素瘤。其中，吩噻嗪类化合物的通式为：其中，R1为R2为其中，n＝1、2、3或4；X为O或N。
• [EN] INHIBITORS OF MALT1 PROTEASE<br/>[FR] INHIBITEURS DE LA PROTÉASE MALT1
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2014086478A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds which are inhibitors of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALTl) and to their use in therapy, in particular in the treatment or prevention of a disease or disorder which is treatable by an inhibitor of a paracaspase. The present invention also relates to pharmaceutical compositions containing such compounds.

  本发明涉及作为粘膜相关淋巴组织淋巴瘤易位蛋白1（MALT1）抑制剂的化合物及其在治疗中的应用，尤其是在治疗或预防可通过抑制paracaspase治疗的疾病或失调中的应用。本发明还涉及含有该化合物的药物组合物。
• Method of reducing blood glucose
  申请人：Novo Nordisk A/S

  公开号：US05741791A1

  公开（公告）日：1998-04-21

  The present invention relates to the use of compounds of the general formula ##STR1## for reducing blood glucose and/or inhibit the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Hence the compound can be used in the treatment of insulin resistance related to NIDDM (non-insulin-dependent diabetes mellitus) or aging.

  本发明涉及使用一般式##STR1##的化合物来降低血糖和/或抑制胰岛素拮抗肽如CGRP或淀粉样蛋白的分泌、循环或作用。因此，该化合物可用于治疗与NIDDM（非胰岛素依赖型糖尿病）或衰老相关的胰岛素抵抗。
• N-substituted azaheterocyclic carboxylic acids and esters thereof
  申请人：Novo Nordisk A/S

  公开号：US05595989A1

  公开（公告）日：1997-01-21

  The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

  本发明涉及新颖的N-取代的氮杂环羧酸及其酯，其中取代烷基链构成N-取代物的一部分或其盐，以及它们的制备方法，含有它们的组合物，以及它们在临床治疗疼痛、过敏性疼痛和/或炎症病况中的应用，其中C-纤维通过引发神经源性疼痛或炎症发挥病理生理作用。
• Electrochromic compound
  申请人：NTERA limited

  公开号：US07358358B2

  公开（公告）日：2008-04-15

  A compound for use in electrochromic devices. The compound includes (1) β-(10-phenothiazyl)propoxy phosphonic acid; (2) β-(10-phenothiazyl)propyl-phosphonic acid; and (3) β-(10-phenothiazyl)propionate phosphonic acid.

  用于电致变色器件的化合物。 该化合物包括（1）β-(10-苯并噻吩基)丙氧基膦酸；（2）β-(10-苯并噻吩基)丙基膦酸；和（3）β-(10-苯并噻吩基)丙酸膦酸。